This Pre-Solicitation opportunity from Department Of Health And Human Services was posted on July 30, 2026. The submission period has ended. Browse the details below for market research, or find similar active opportunities.
IR System Add-ons (Microplastics)
Contract Overview
Solicitation details, issuing organization, response deadlines, documents, and interested companies for this government contract opportunity.
Active Opportunities Like This One
AI Contract Overview
The U.S. Food and Drug Administration is procuring a counter-propagating mode upgrade for its existing Photothermal mIRageLS microscope under a sole-source, non-competitive acquisition, justified by the exclusive ownership of Optical Photothermal Infrared (O-PTIR) technology by Photothermal Spectroscopy Corp. (PSC), the only entity capable of delivering full system compatibility with the FDA’s current instrumentation. This upgrade, intended for the detection of microplastics and nanoplastics in human foods, requires seamless integration into the existing software platform and must enable electronic switching between co- and counter-propagating imaging modes with sub-500 nm spatial resolution, a capability uniquely provided by PSC through its patented technologies. The acquisition is constrained to PSC due to its exclusive patent portfolio, manufacturer-specific authorization requirements for installation and qualification, and the impossibility of achieving technical functionality with any other vendor. As a registered small business with CAGE code 83PQ8 and NAICS code 334516, PSC is the sole responsible source, and the procurement is structured as a Firm-Fixed-Price purchase order under simplified acquisition procedures, valued between $25,001 and $250,000. Performance is to occur at the FDA’s facility in College Park, Maryland, with acceptance criteria centered on functional integration, software compatibility, and manufacturer-authorized commissioning. No competition is permitted or practicable, and all responders must demonstrate formal authorization from PSC to distribute and service the O-PTIR system, alongside proof of small business status and prior contract performance. The presolicitation was issued on July 30, 2026, with a deadline for capability statements on August 13, 2026, and an anticipated award date no later than September 9, 2026. Communication and submissions are handled exclusively via email to designated FDA contracting personnel, with no formal contract clauses, detailed pricing, or logistical specifications provided at this stage.
General Info
Agency
NAICS
Place of Performance
College Park, MD, 20740, USASet-Aside
Timeline
Submission Closed
Organization & Contact Information
Full Description
Pursuant to RFO 5.101(c)(4)(vii), the following identifies the intended source and explains why competition is not practicable for this requirement.
Intended Contractor:
Photothermal Spectroscopy Corp.
325 Chapala St Santa Barbara, CA 93101
CAGE Code: 83PQ8
The basis for limiting this solicitation to a single source is that only one source is reasonably available, consistent with RFO 13.101(b) and the single-source standard at RFO 12.201-1(c).
Photothermal Spectroscopy Corp “PSC” is the one and only supplier that can meet the performance requirements outlined in the Statement of Work. The counter-propagating mode upgrade must be 100% compatible with the existing Photothermal mIRageLS to provide a seamless integration and establish full system communication and control through the single, existing software currently at FDA. PSC owns the patent for intellectual property protecting the O-PTIR technology and its associated capabilities. O-PTIR is protected by multiple patents and is exclusively available from Photothermal Spectroscopy. PSC will be the only provider to support the FDA in this requirement of the necessary parts and knowledgeable installation team to ensure 100% compatibility of the upgrade with the current FDA instrument. Photothermal is a US company and is a registered small business. A Brand Name acquisition is recommended, since only one provider meets the requirements for the acquisition.
A written single-source justification has been prepared and approved in accordance with RFO 12.201-1(c) and RFO 13.101(b).
More opportunities from Department Of Health And Human Services → FDA Office Of Acq Grant Svcs
Same awarding agency
Find Active Opportunities Like This
Get AI-powered intelligence on the opportunities still open
Every page of the solicitation package shredded into a compliance breakdown
AI-powered matching based on your capabilities and past performance
Competitor and incumbent history on the requirement
Automated alerts on amendments, Q&A deadlines, and award
Join 650+ contractors already using CLEATUS
